

Ref: FOI/GS/ID 8505

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

15 December 2023

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast Cancer.

*You asked:*

*Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?*

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

- 1.1 Abemaciclib (Verzenios)*
- 1.2 Alpelisib (Piqray)*
- 1.3 Fulvestrant (fulvestrant or Faslodex)*
- 1.4 Palbociclib (Ibrance)*
- 1.5 Ribociclib (Kisqali)*

*Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?*

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

*Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?*

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

*Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?*

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

- 4.1 Curative*

4.2 Palliative

4.3 Not known / stated

Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)

5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)

5.3 Abemaciclib (Verzenois) + tamoxifen

5.4 Abemaciclib monotherapy

5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)

5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)

5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)

5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)

5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)

Trust response:

1.

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	29
1.2 Alpelisib (Piqray)	0
1.3 Fulvestrant (fulvestrant or Faslodex)	31
1.4 Palbociclib (Ibrance)	84
1.5 Ribociclib (Kisqali)	16

Q2. 2

Q3. 2

Q4.

Curative = 0

Palliative = 0

Not known/stated = 0

Q5.

5.1 - 0

5.2 - 6

5.3 - 1

5.4 - 0

5.5 - 0

5.6 - 0

5.7 - 0

5.8 - 2

5.9 - 5